How Long Does Olanzapine Stay in Your System?

Oral olanzapine has an average half-life of about 33 hours, which means it takes roughly seven to eight days after your last dose for the drug to be effectively cleared from your bloodstream. That timeline can shift considerably depending on whether you smoke, how well your kidneys work, and which formulation you received. If you were given the long-acting injectable form, the picture changes dramatically, with detectable levels persisting for months.

The 33-Hour Half-Life and What It Means

After you swallow an olanzapine tablet, the drug is almost entirely absorbed from the gut, but first-pass metabolism in the liver cuts the amount that actually reaches your circulation to about 60%. Blood levels peak roughly six hours after a dose. From that point, the drug’s concentration drops by half every 33 hours or so.¹ A common rule of thumb in pharmacology is that it takes about five half-lives for a drug to drop below clinically meaningful levels. For olanzapine, five half-lives works out to roughly 165 hours, or just under seven days. Extending that to six half-lives puts you closer to eight days.

That said, “effectively cleared” and “completely undetectable” are not the same thing. Sensitive laboratory equipment can pick up trace amounts well past the point where the drug stops doing anything in your brain. And the 33-hour average is exactly that, an average. Individual half-lives in published studies range from the low 20s to over 50 hours, depending on the person.

Why Olanzapine Lingers So Long

Two properties of the drug help explain why it sticks around. First, olanzapine is highly fat-soluble. It leaves the blood quickly and distributes widely into body tissues, with a volume of distribution reported at roughly 16 liters per kilogram of body weight.¹ In practical terms, this means the drug spreads into fat and organ tissue far beyond the bloodstream, and those tissue reservoirs slowly release it back into circulation even after you stop taking it.

Second, olanzapine is heavily protein-bound, mainly to albumin and another carrier protein in the blood. Only the unbound fraction is available to be filtered by the kidneys or broken down by the liver. Less than 10% of the drug is excreted by the kidneys in its original form; the vast majority is metabolized in the liver before it leaves the body. This is why liver function and anything that affects liver enzymes can change how long the drug stays in your system.

Smoking, Kidneys, and Other Factors That Speed Up or Slow Down Clearance

If you smoke cigarettes, you clear olanzapine faster than a nonsmoker. The reason is that chemicals in cigarette smoke (not the nicotine itself, but the polycyclic aromatic hydrocarbons from combustion) rev up the liver enzyme primarily responsible for breaking olanzapine down. A meta-analysis estimated that a smoker taking 10 mg per day of olanzapine reaches roughly the same blood levels as a nonsmoker taking about 7 mg per day.² At 20 mg per day in a smoker, the equivalent nonsmoker dose was estimated at about 14 mg per day. A separate study of 71 patients with schizophrenia confirmed the gap: after controlling for age and sex, smokers had significantly lower dose-corrected blood levels than nonsmokers.³

The clinical consequence cuts both ways. If you quit smoking while on olanzapine, your blood levels may rise noticeably within a week or two as that enzyme activity drops back down, potentially increasing side effects. If you start smoking, your levels could fall enough to reduce the drug’s effectiveness. Clinicians who manage olanzapine dosing pay close attention to changes in smoking status for this reason.

Kidney function is another modifier, though its impact on olanzapine is more modest than you might expect for a drug cleared mainly by the liver. In people with severe kidney impairment, olanzapine clearance dropped by about a third and overall drug exposure rose by roughly 50% compared with healthy controls.⁴ Pharmacokinetic modeling predicted that at steady state, mild kidney impairment raises olanzapine exposure by about 20%, moderate impairment by about 50%, and severe impairment by roughly 60%.⁵ These numbers mean that someone with serious kidney disease carries the drug for longer and reaches higher peak levels on the same dose.

Age and sex are sometimes mentioned as clearance factors. The data on these are less consistent. Some pharmacokinetic analyses have found modest differences, but the smoking and kidney effects tend to overshadow them in clinical practice.

The Long-Acting Injection Stays for Months

Olanzapine pamoate, the long-acting injectable form given as an intramuscular shot, behaves very differently from the oral tablet. The salt form creates a slow-dissolving depot in the muscle tissue. Instead of a half-life measured in hours, the injectable version has an apparent half-life of about 30 days.⁶ That long half-life is controlled not by how quickly the liver breaks olanzapine down, but by how slowly the drug seeps out of the injection site into the bloodstream.⁷

After the last injection, it can take six to eight months for the absorption and distribution of the depot to fully complete.⁶ Using the five-half-life rule on a 30-day half-life gives roughly 150 days, or about five months, for the drug to drop to negligible levels. In practice, detectable concentrations can persist for half a year or longer. This is an important consideration if you are switching medications, planning a pregnancy, or dealing with side effects, because you cannot simply stop the drug and have it wash out in a week the way oral olanzapine does.

Does Olanzapine Show Up on Drug Tests?

Standard workplace and forensic drug screening panels do not test for antipsychotics. The typical five- or ten-panel urine test screens for substances like amphetamines, opioids, cannabinoids, cocaine, and benzodiazepines. Olanzapine will not trigger a positive result on any of these, although a handful of older case reports have noted rare false positives for benzodiazepines on immunoassay screens that were subsequently ruled out by confirmatory testing.

When olanzapine urine testing is specifically ordered, which is uncommon and usually limited to therapeutic compliance monitoring in psychiatry, the drug can be detected. In a pilot study of patients known to be taking antipsychotics, urine concentrations of olanzapine ranged from 57 to 700 ng/mL, and all samples tested positive.⁸ However, there are no widely established cutoff levels or detection windows for olanzapine in urine the way there are for drugs of abuse. The test exists as a specialty assay, not something you would encounter in routine employment or legal screening.

Blood (serum or plasma) testing for olanzapine is more common in clinical settings and is used for therapeutic drug monitoring. The accepted therapeutic range is roughly 20 to 40 ng/mL, with adverse effects becoming more likely above 80 ng/mL and levels above 100 ng/mL considered an alert threshold.⁹ A large meta-analysis found that people who responded well to the drug had mean plasma concentrations around 30 µg/L, compared with about 22 µg/L in nonresponders.¹⁰ These numbers matter more for dose optimization than for detection windows, but they give a sense of the blood levels expected while someone is actively taking the drug.

After an Overdose, the Rules Change

If someone has taken a large overdose of olanzapine, the usual 33-hour half-life may not apply. At very high doses, the liver’s capacity to metabolize the drug becomes saturated, and elimination shifts from a predictable single-phase decline to something more drawn out. A case report documenting serial blood levels after a non-fatal overdose found a two-phase elimination pattern: an initial phase with a half-life of about 24 hours lasting the first three days, followed by a slower second phase with a half-life of roughly two and a half days.¹¹ That slower second phase extends the total clearance time well beyond what the standard half-life would predict.

The practical takeaway for emergency and critical care settings is that monitoring should continue longer than might seem necessary based on the drug’s normal pharmacokinetics. Sedation, low blood pressure, and rapid heart rate can persist or recur as the drug redistributes from tissues back into the blood. The recommendation from toxicology literature is to track serum levels after an overdose rather than relying on the textbook half-life to predict when the patient will be in the clear.

What Happens at the Receptor Level When You Stop

Even after the drug has dropped to low blood levels, its effects on the brain do not disappear in a straight line. Olanzapine works primarily by blocking dopamine D2 receptors, and the relationship between the amount of drug in your blood and the degree of receptor blockade is not proportional. Brain imaging studies using PET scans have shown that this relationship follows a curve where relatively low plasma levels can still occupy a surprisingly high percentage of receptors.¹² In plain terms, cutting your dose in half does not cut receptor blockade in half. At higher doses, you are already near a ceiling of receptor occupancy, so the first reductions barely change what is happening in the brain. At lower doses, each small reduction has a bigger proportional effect.

This matters for anyone tapering off olanzapine. A gradual, slow taper, especially at the lower dose range, gives the brain’s dopamine system more time to readjust. Some clinicians now advocate for hyperbolic dose reduction schedules that make smaller and smaller cuts as the dose gets lower, rather than the traditional approach of reducing by the same absolute amount each time. The drug might be nearly gone from your blood within a week, but the neurochemical adjustments your brain needs to make can take considerably longer.

Olanzapine and Breastfeeding

For nursing mothers, the question of how long the drug stays in the system extends to what reaches the infant through breast milk. Available evidence, though limited, has been reassuring. Maternal doses of up to 20 mg per day produced low levels in breast milk and undetectable levels in the blood of breastfed infants.¹³ Sedation, which would be the most obvious sign of drug exposure in the infant, has not been reported in published follow-up studies. Still, because olanzapine has a relatively long half-life and sedative properties, the general advice is to watch for lethargy and developmental milestones in the baby, especially if the mother is taking more than one sedating medication.

It is worth noting that the drug’s fat solubility, the same property that gives it a large volume of distribution in adults, could in theory allow some accumulation in the fat-rich tissue of breast milk. The reassuring infant blood-level data suggests this does not translate into clinically meaningful infant exposure at standard maternal doses, but it underscores why monitoring is still recommended.

Therapeutic Drug Monitoring in Practice

Most people taking olanzapine never get their blood levels checked. But therapeutic drug monitoring can be genuinely useful in specific situations: when someone is not responding to what should be an adequate dose, when side effects seem excessive relative to the dose, when there is a question about whether a patient is actually taking their medication, or when a factor like smoking status or kidney disease changes. A study of 61 patients found that the majority, about two-thirds, actually had blood levels below the therapeutic range, while only a small fraction had levels high enough to raise concern about toxicity.⁹ This suggests that dosing by milligrams alone misses a lot of individual variation.

The meta-analysis on olanzapine plasma concentrations and treatment response adds another dimension. Using individual patient data, the researchers identified that a plasma level around 22 to 23 µg/L was the threshold most strongly associated with a meaningful clinical response. Above about 56 µg/L, the probability of a poor response actually climbed, suggesting a therapeutic ceiling.¹⁰ The relationship between blood levels and clinical benefit is not a simple “more is better.” There is a sweet spot, and individual metabolic differences mean two people on the same dose can land in very different places.

For the original question of how long the drug stays in your system, this data reinforces that “clinically active” and “detectable” are separate thresholds. Blood levels below 20 ng/mL are considered subtherapeutic, so once you drop below that range after stopping, the drug is unlikely to be producing meaningful receptor blockade. But trace amounts remain measurable for longer, and the exact timeline depends on which of the factors discussed above apply to you.